RLS-1496
Actinic Keratosis
Phase 1Active
Key Facts
About Rubedo Life Sciences
Rubedo Life Sciences is a private, clinical-stage biotech pioneering a novel approach to longevity by targeting pathologic cells like senescent cells that drive aging and chronic diseases. The company has advanced its lead candidate, RLS-1496, a first-in-class GPX4 modulator, into Phase 1 clinical trials for actinic keratosis, with an FDA-cleared IND. Backed by a proprietary discovery platform (ALEMBIC™) and experienced leadership, including a former Allergan executive as CEO, Rubedo is positioning itself at the forefront of the rapidly growing longevity therapeutics market.
View full company profileTherapeutic Areas
Other Actinic Keratosis Drugs
| Drug | Company | Phase |
|---|---|---|
| 15dPMJ2 | Claradele Pharmaceuticals | Pre-clinical |
| Skinject Patch | Skinject | Research |
| Bimiralisib (PQR309) | Torqur | Phase 2 |
| VD-001 | Vidac Pharma | Phase 2B |
| Klisyri (tirbanibulin) | Almirall | Marketed |